J&J gains point-of-care testing technology

Acquisition of Swedish in vitro diagnostics firm Amic gives Johnson & Johnson's Ortho-Clinical Diagnostics subsidiary access to development-stage technology for chip-based, micro-fluidic, quantitative immunoassays intended for point-of-care and near-patient settings, the firm announces June 18. The purchase of privately held Amic, terms of which were not disclosed, provides "a strategic opportunity to develop a point-of-care channel" - an area of diagnostics where "double-digit market growth is anticipated," J&J says. The deal will result in a $40 million after-tax charge in J&J's second quarter to account for in-process R&D